Recursion Pharmaceuticals stock dropped 11.1% after brokerage downgrades and a missed EPS.
Recursion Pharmaceuticals has received a "Moderate Buy" consensus from four brokerages, with an average 1-year price target of $12.67. However, recent downgrades include Leerink Partners lowering its target from $9 to $8, and Jefferies cutting theirs from $8 to $6. The company's stock dropped 11.1% after these changes. Recursion reported a quarterly EPS of ($0.40), missing estimates, and insiders sold 255,682 shares recently.
September 03, 2024
11 Articles